Table 1.
Proteins in the literature (since 2007) that have been assayed in plasma/serum from ovarian cancer patients and have known ratios of one year hormone therapy compared to baseline.
| Protein | Log2 Ratio (1-Year HT/Baseline) | P-Value | Reference(s) |
|---|---|---|---|
| AFM | 0.13 | 0.0032 | (5, 7) |
| ALCAM | 0.02 | 0.50 | (12) |
| Cathepsin L | -0.39 (CTSL1) | 0.20 (CTSL1) | (19) |
| CCL18 | -1.62 | 0.060 | (18) |
| CD14 | -0.029 | 0.41 | (12) |
| CLU | 0.087 | 0.00094 | (6) |
| CST3 | 0.059 | 0.012 | (6) |
| FBLN1 | -0.032 | 1.00 | (19) |
| Fibrinogen | 0.34 (FGA) | 0.00056 (FGA) | (19) |
| 0.24 (FGB) | 0.06 (FGB) | ||
| FN1 | -0.28 | 0.0031 | (19) |
| GRN | 0.068 | 0.42 | (12) |
| Hemoglobin | 0.34 (HBA) | 0.45 (HBA) | (19) |
| 0.11 (HBB) | 0.60 (HBB) | ||
| 0.021 (HBD) | 0.55 (HBD) | ||
| IGF1 | -0.36 | 4.81E-05 | (13) |
| IGF2 | -0.035 | 0.36 | (9, 11, 16, 19) |
| IGFBP1 | 0.92 | 0.00023 | (3, 10) |
| IGFBP2 | -0.34 | 0.025 | (12) |
| IGFBP3 | -0.070 | 0.038 | (13, 17) |
| IGFBP4 | 0.35 | 0.010 | (6, 17) |
| IGFBP5 | -0.074 | 0.036 | (6, 17) |
| IGFBP6 | 0.15 | 0.033 | (6) |
| IGFBP7 | -0.20 | 0.0021 | (6) |
| Inhibin (total) | 0.25 (INHBC) | 0.036 (INHBC) | (15, 19) |
| 0.38 (INHBE) | 0.0083 (INHBE) | ||
| ITIH4 | 0.42 | 0.00018 | (19) |
| LCN2 | 0.18 | 0.15 | (11, 12) |
| MIF | -0.041 | 0.73 | (11, 16) |
| MMP2 | -0.59 | 0.41 | (10, 17) |
| NOV | -0.49 | 0.0053 | (12) |
| PI3 | 0.24 | 0.082 | (12) |
| PPBP | 0.13 | 0.014 | (12) |
| RARRES2 | 0.15 | 0.039 | (12) |
| TGFB1 | -0.015 | 0.43 | (12) |
| THBS1 | 0.23 | 0.24 | (12) |
| TIMP1 | -0.29 | 0.019 | |
| TIMP2 | -0.0090 | 0.86 | |
| TNFRSF21 | -0.11 | 0.26 | (12) |
| VASN | -0.39 | 0.0044 | (6) |
| VCAM1 | -0.084 | 0.17 | (10, 12) |
| VEGF | -0.81 (VEGFC) | 0.082 (VEGFC) | (14) |
| VWF | -0.039 | 0.44 | (12) |
| WFDC2 (HE4) | -0.055 | 0.97 | (4, 11, 19) |